STADA Arzneimittel AG

What STADA Arzneimittel AG does

STADA Arzneimittel AG is a German-headquartered, privately-held pharmaceutical company operating across three pillars: Consumer Healthcare, Generics, and Specialty Pharmaceuticals. Founded in 1895 as a pharmacists' cooperative and headquartered in Bad Vilbel, Germany, the company manufactures and distributes branded over-the-counter products (Nizoral, Grippostad, Zoflora, Silomat, Hirudoid, Lunestil), affordable generic medicines (where it ranks fourth in Europe by sales), and a growing biosimilars portfolio (adalimumab, ustekinumab, golimumab/Gotenfia, bevacizumab, pegfilgrastim, teriparatide, ranibizumab, epoetin zeta, denosumab) developed with partners including Alvotech, Bio-Thera, Xbrane, and CuraTeQ. Specialty Pharmaceuticals surpassed €1 billion in revenue in 2025 with 17% YoY growth, led by orphan drug Kinpeygo for IgA nephropathy and biosimilar Uzpruvo.

The company sells in over 100 countries through wholly-owned subsidiaries, pharmacy distribution networks, and channel partnerships (notably Sanofi for 20 European and 10 Eurasian countries). It employs 11,749 people worldwide and reported FY2025 adjusted revenues of €4.3 billion with adjusted EBITDA of €961 million. The business model relies on branded and generic pharmaceutical sales, licensing/distribution fees, and royalty income from in- and out-licensed products.

In March 2026, CapVest Partners LLP completed a €10 billion majority acquisition, returning STADA to private ownership under a sponsor with stated intent to accelerate growth via M&A. Subsequent deals include the €85 million Saudi Arabia manufacturing hub (February 2026), Locobase derma line acquisition (May 2026), and the Orifarm VMS portfolio acquisition of 16 brands (June 2026). The company also deploys an AI-powered Lean Auditing system that reduces supplier audit reporting time by 40%, saving more than 11,000 hours annually.

Name

STADA Arzneimittel AG

Legal name

STADA Arzneimittel AG

Website

https://stada.com

Company type

Private

Founded year

1895

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

STADA Arzneimittel AG is a German pharmaceutical company founded in 1895 that develops, manufactures, and distributes Consumer Healthcare products, generics, and specialty pharmaceuticals including biosimilars across 100+ countries. It serves patients, pharmacists, and healthcare systems, generating €4.3 billion in FY2025 revenue.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Generic pharmaceuticals
• Consumer healthcare products
• Biosimilar medicines
• Specialty pharmaceuticals
• OTC medications

Headquarters

HQ city

Bad Vilbel

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceuticals: STADA's generic drugs business is the backbone of the company since 1895. As the fourth-largest generics manufacturer and supplier in Europe by sales, STADA provides affordable versions of branded medications, with seven out of ten medicines prescribed in Europe being generics accounting for about 30% of pharmaceutical expenditure.
2. Consumer Healthcare Products: OTC products including Nizoral (dandruff/scalp care), Grippostad (cough/cold), Zoflora (disinfectants), Silomat (cough relief), Hirudoid (pain relief), Lunestil (sleep), and vitamins/minerals/gastro products sold through pharmacies and retail.
3. Specialty Pharmaceuticals: High-value innovative medicines for chronic, severe, or rare diseases including biosimilars (adalimumab, ustekinumab, golimumab, bevacizumab, pegfilgrastim, teriparatide, ranibizumab), oncology products, and orphan drugs. The specialty segment surpassed €1 billion in revenue in 2025 with 17% growth.
4. Licensing and Distribution Agreements: STADA generates revenue through in-licensing and out-licensing arrangements, including partnerships with Bio-Thera (Gotenfia), Alvotech (biosimilars), and distribution agreements with Sanofi, covering various geographies including Europe and emerging markets.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels9 records

Core offering

STADA Arzneimittel AG manufactures, markets, and distributes a diversified pharmaceutical portfolio across three pillars: Consumer Healthcare (OTC brands such as Nizoral, Grippostad, Zoflora, Silomat, Hirudoid, Lunestil), Generics (affordable off-patent medicines as Europe's fourth-largest generics manufacturer), and Specialty Pharmaceuticals (biosimilars and innovative treatments for oncology, immunology, nephrology, ophthalmology, bone health, and neurology). Products are sold in over 100 countries through pharmacy networks, retail channels, e-commerce, and distribution partnerships with major pharma companies including Sanofi, Alvotech, Bio-Thera, and Xbrane.

Product overview

STADA Arzneimittel AG is a leading global healthcare and pharmaceuticals company with a three-pillar strategy spanning Consumer Healthcare products, Generics, and Specialty Pharmaceuticals. The company operates in over 100 countries with approximately 11,749 employees, achieving adjusted group revenues of EUR 4.3 billion and adjusted EBITDA of EUR 961 million in financial year 2025. The Consumer Healthcare portfolio includes major brands such as Nizoral (anti-dandruff/scalp care), Grippostad (cold/flu), Zoflora (disinfectants), Snup (nasal spray), Silomat (cough relief), Lunestil (sleep aids), and acquired brands including Nycoplus, Apovit, and Vitrum (VMS). The Specialty Pharmaceuticals segment offers innovative treatments and biosimilars within therapeutic areas including oncology (bevacizumab, pegfilgrastim), nephrology (Kinpeygo for IgA nephropathy, epoetin zeta), neurology (Parkinson's combination therapies), immunology (adalimumab, ustekinumab biosimilars), bone health (teriparatide), and ophthalmology (ranibizumab). The Generics segment provides affordable medications as the fourth-largest generics supplier in Europe. Recent strategic acquisitions include the Orifarm VMS portfolio and Locobase derma line, with partnerships spanning Alvotech, Bio-Thera, Xbrane, CuraTeQ, and others.

Differentiator

Problem solved

Functional benefit

Brands

• Nizoral: Medical treatment against dandruff; anti-dandruff brand in EMEA markets
• Grippostad
• Zoflora
• Silomat
• Hirudoid
• Lunestil
• SNUP
• Covonia
• Synthol
• Cetebe
• Orofar
• Oilatum
• BIOPRON
• Kinpeygo
• Uzpruvo
• Gotenfia
• Movymia

Products and services

• Nizoral Medical treatment against dandruff with clinically proven efficacy and long-lasting relapse prevention for scalp care, sold through European pharmacies.
• Grippostad Medicine against flu infections and colds, sold through pharmacies.
• Zoflora Disinfectant to keep households clean from harmful bacteria.
• Snup Nasal spray medicine for decongestion of colds.
• Silomat Relief of irritating, dry coughs.
• Hirudoid Topical treatment for venous insufficiency and phlebology, joint and muscular pain.
• Lunestil Sleeping pills for short-term treatment of acute sleep disorders.
• Covonia Cough and cold remedy brand.
• Synthol Pain relief product.
• Cetebe Vitamins and minerals supplement for gastrointestinal health.
• Oilatum Dermatology product for skincare including cracked, dry and eczema-prone skin.
• BIOPRON Premium probiotics and vitamins/minerals/gastro supplements.
• ColdZyme Oral spray medical device for cold and flu symptoms, distributed by STADA in Germany and Austria under partnership with Enzymatica.
• Nycoplus Market-leading pharmacy vitamins, minerals and supplements (VMS) line in Norway, acquired from Orifarm.
• Apovit Market-leading VMS range in Danish pharmacies, acquired from Orifarm.
• Vitrum Broad VMS brand in Poland, acquired from Orifarm.
• Locobase Derma Line Dermatology product line in the Nordics, acquired to strengthen consumer healthcare leadership in Europe.
• Kinpeygo Innovative targeted-release formulation of budesonide for treatment of primary immunoglobulin A nephropathy (IgAN), a rare kidney disease. First medicine approved in EU for this indication.
• Uzpruvo (Ustekinumab Biosimilar) Ustekinumab biosimilar, Europe's first ustekinumab biosimilar, for autoimmune diseases with continued double-digit expansion across more than 20 markets.
• Adalimumab Biosimilar High-concentration adalimumab biosimilar for autoimmune diseases including rheumatoid arthritis and psoriasis, available in Europe.
• Bevacizumab Biosimilar Biosimilar for cancer treatment, launched with focus on Europe and available in Germany and Netherlands with expansion to other European countries.
• Pegfilgrastim Biosimilar Biosimilar for cancer patients with neutropenia.
• Movymia (Teriparatide Biosimilar) Biosimilar teriparatide for treatment of osteoporosis, launched in 24 countries in partnership with Richter-Helm.
• Ranibizumab Biosimilar Biologic ophthalmic medicine for ophthalmologic conditions, launched in Europe in partnership with Xbrane.
• Gotenfia (Golimumab Biosimilar) Golimumab biosimilar referencing Johnson & Johnson's Simponi, approved for chronic inflammatory autoimmune diseases including rheumatoid arthritis and ulcerative colitis.
• AVT03 (Denosumab Biosimilar) Biosimilar to Prolia and Xgeva (denosumab) for osteoporosis and oncology treatments, marketed through partnerships with STADA and Dr. Reddy's.
• Bortezomib STADA Anti-cancer drug launched in 14 European countries as first generic and innovative ready-to-use injection solution.
• STADA Generics Affordable generic pharmaceutical products containing the exact active pharmaceutical ingredient as original patented products at substantially lower prices; STADA is the fourth-largest manufacturer and supplier of generics in Europe.
• Levodopa-Carbidopa-Entacapone Combination (Parkinson's) Device-driven combination for late-stage Parkinson's disease therapy, including new triple combination product with modern pump technology.

Quantifiable outcome

• STADA doubled e-commerce sales between 2022 and 2025
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eleven partnerships are on record, tiered major and core.

• Enzymatica ABmajorChannel Partner/ Reseller/ Distributor · 1 April 2026Swedish life science company Enzymatica AB partnered with STADA for the launch and distribution of Enzymatica's ColdZyme oral spray medical device in Germany and Austria. STADA markets the product under its own brand names through its established commercial platform, with commercial impact expected from the 2026/2027 cold and flu season.
• CuraTeQ Biologics (Aurobindo Pharma)coreStrategic or Co-development Partner · 30 March 2026Aurobindo Pharma's biosimilars arm CuraTeQ Biologics partnered with STADA to market and distribute two EMA-approved biosimilars (for neutropenia) in select EU territories including France and Germany under new brand names. The partnership aims to expand CuraTeQ's market presence in Europe.
• Bio-Thera SolutionscoreStrategic or Co-development Partner · 13 February 2026STADA and Bio-Thera received European Commission marketing authorization for Gotenfia (golimumab), a biosimilar to Johnson & Johnson's Simponi, approved for multiple chronic inflammatory autoimmune diseases. Bio-Thera developed and manufactures the product while STADA holds exclusive rights to commercialize it across the EU, UK, Switzerland and selected other countries. Gotenfia was the second golimumab biosimilar approved in the EU. Bio-Thera previously granted STADA exclusive commercialization rights in a deal worth up to USD 157.5 million plus royalties.
• XbranemajorStrategic or Co-development Partner · 1 April 2023Partnership with Sweden's Xbrane to bring the biologic ophthalmic medicine ranibizumab to patients in Europe, supporting patient access to eye disease treatments.
• AdalvomajorStrategic or Co-development Partner · 1 January 2023Extension of a strategic partnership with Adalvo to obtain commercial rights in Europe to five additional active ingredients in therapeutic categories including oncology and diabetes.
• AlvotechcoreStrategic or Co-development Partner · 1 December 2022Strategic partnership with Iceland's Alvotech to expand patient access to adalimumab biosimilar (for autoimmune conditions) in Europe, and to submit marketing authorization for ustekinumab biosimilar (AVT04, proposed biosimilar to Stelara). Also partnered with Alvotech for AVT03 (denosumab biosimilar, Prolia/Xgeva) commercialized in Europe.
• Calliditas Therapeutics ABcoreStrategic or Co-development Partner · 1 September 2021STADA partnered with Sweden's Calliditas to obtain the first approval in the EU for a treatment for the rare kidney disease immunoglobulin A nephropathy (IgAN). STADA commercializes Kinpeygo (targeted-release budesonide) for this indication in Europe. In 2026, STADA hosted a symposium on IgA nephropathy at ERA 2026 with over 1,350 participants.
• SanoficoreChannel Partner/ Reseller/ Distributor · 1 July 2021STADA acquired 16 well-established consumer healthcare brands from Sanofi and entered a distribution agreement to market and distribute Sanofi's entire consumer healthcare portfolio in 20 European countries and 10 Eurasian countries. This partnership strengthened STADA's position as a leading Consumer Healthcare company in Europe.
• mAbxiencemajorStrategic or Co-development Partner · 1 March 2021STADA partnered with mAbxience to expand its specialty oncology portfolio with the launch of biosimilar bevacizumab, available to oncologists and their patients in Germany and the Netherlands with launches in other European countries following.
• Richter-Helm BioTecmajorStrategic or Co-development Partner · 1 August 2019STADA collaborates with Richter-Helm-BioTec GmbH & Co.KG on the in-licensing of teriparatide for the treatment of osteoporosis, expanding its biosimilar portfolio. Movymia (teriparatide biosimilar) was launched in 24 countries.
• GlaxoSmithKline (GSK)coreChannel Partner/ Reseller/ Distributor · 1 January 2019STADA acquired 15 well-established consumer healthcare brands from GSK across more than 40 countries, following a previous deal for five non-prescription skincare brands. This transaction made STADA a major Consumer Healthcare player.

Scale indicators13 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Sandoz: Sandoz, spun out of Novartis in 2023, is the world's largest generics and biosimilars company with a comparable European footprint and biosimilar pipeline (hyrimoz, eculizumab, Omnitrope) that competes head-to-head with STADA's adalimumab, pegfilgrastim, and other biosimilars in EU tenders.
• Teva Pharmaceutical Industries: Teva is the largest global generics manufacturer with a broad European generics portfolio, OTC brands, and a biosimilar pipeline (Truxima, Herzuma), overlapping directly with STADA's three-pillar generics/CHC/specialty model across Germany, Eastern Europe, and Eurasia.
• Viatris: Viatris (Mylan-Upjohn combination) is a top-three global generics player with significant European presence across retail generics, biosimilars, and branded complex generics, directly comparable to STADA's generics and specialty portfolio and competitive in the same tender markets.
• KRKA: KRKA is a Slovenia-based generics manufacturer with strong Central and Eastern European market positions and an expanding consumer healthcare and biosimilar footprint, making it a close geographic and portfolio peer to STADA in CEE markets like Poland, Czechia, and the Balkans.
• Hikma Pharmaceuticals: Hikma is a UK-listed generics and specialty manufacturer with significant operations across Europe, the Middle East, and North America; its branded generics, injectables, and biosimilar pipeline closely parallel STADA's specialty and generics strategy and overlap in MENA and European markets.
• Polpharma Group: Polpharma is one of the largest pharmaceutical manufacturers in Central and Eastern Europe with a generics-led portfolio and growing OTC presence, making it a regional direct competitor to STADA in Poland, Russia, and CIS markets.

Emerging players

• Alvotech: Alvotech is a pure-play biosimilar developer partnering with STADA on adalimumab (high-concentration), ustekinumab (AVT04), and denosumab (AVT03); while a partner today, it competes with STADA in tenders and represents a hybrid peer-and-supplier relationship for biosimilars.
• Bio-Thera Solutions: Bio-Thera is a Chinese biosimilar developer that partnered with STADA for Gotenfia (golimumab) commercialization in EU/UK/Switzerland; it is a current partner but competes in the broader biosimilar development landscape and signals emerging Asia-based competition for STADA's specialty pipeline.

Broad incumbents

• Perrigo Company: Perrigo is a global OTC consumer healthcare leader with a European store-brand and self-care portfolio that overlaps directly with STADA's CHC brands (Nizoral, Grippostad, Zoflora) in European pharmacy and retail channels.
• Bayer Consumer Health: Bayer's Consumer Health division is a global OTC powerhouse with leading European brands across cough/cold, dermatology, and pain — competing with STADA's Grippostad, Silomat, Hirudoid, and Oilatum in the same European pharmacy shelves.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/stada
• YouTubeyoutube.com/user/STADAArzneimittelAG
• Facebookfacebook.com/stada
• LinkedInlinkedin.com/company/stada
• Instagraminstagram.com/stadagroup

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries16 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A10 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about STADA Arzneimittel AG